To evaluate the characteristics and the therapeutic efficacy and safety of (lenvatinib) LEN as a second-and third-line treatment for unresectable hepatocellular carcinoma patients in clinical settings.
Latest Information Update: 10 Jul 2020
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 19 May 2020 Results (n=57) published at Gastroenterology in conjunction with Digestive Disease Week 2020
- 27 Feb 2020 New trial record
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium